Reaffirming financial guidance, especially when it aligns with or exceeds analyst estimates, is typically viewed positively by the market. This reaffirmation by PTC Therapeutics could bolster investor confidence, potentially leading to a positive short-term impact on its stock price. The close alignment with analyst estimates suggests that the company is on track to meet expectations, which is crucial for maintaining or improving stock valuation in the short term.